Maladie résiduelle

Hematologie

Volumn 2, Issue 2, 1996, Pages 153-168

  Baruchel, André ^a   Bastard, Christian ^b   Beldjord, Kheïra ^c   Campos, Lydia ^d   Cavé, Hélène ^e   Cayuela, Jean Michel ^a   Chomienne, Christine ^a   Dastugue, Nicole ^f   Delfau, Marie Hélène ^g   Gabert, Jean ^h   Gorin, Norbert Claude ⁱ   Granchamp, Bernard ^e   Guyotat, Denis ^d   Macintyre, Elisabeth ^j   Preudhomme, Claude ^k   Reiffers, Josy ^l   Sigaux, François ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b CRTS   (France)

^c Hopital Laennec   (France)

^d HÔPITAL NORD   (France)

^e HÔPITAL ROBERT DEBRÉ   (France)

^f CHU PURPAN   (France)

^g HENRI MONDOR HOSPITAL   (France)

^h INSTITUT PAOLI CALMETTES   (France)

ⁱ HÔPITAL SAINT ANTOINE   (France)

^j HÔPITAL NECKER ENFANTS MALADES   (France)

^k CHRV   (France)

^l Hopital Sud Pessac   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CYTOGENETICS; HEMATOLOGIC DISEASE; HUMAN; IMMUNOPHENOTYPING; MINIMAL RESIDUAL DISEASE;

EID: 0029897572     PISSN: 12647527     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (88)

1. Kantarjian HM, Deisseroth A, Kurzrock R, Zstrov Z, Talpaz M. Chronic myelogenous leukemia : a concise update. Blood 1993 ; 82 : 691-703.
2. Freireich EJ, Cork A, Stass SA, McCredie KB, Keating MJ, Estey EH, Kantarjian HM, Trujillo JM. Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia. Leukemia 1992 ; 6 : 500-6.
3. Kibbelaar RE, Mulder JWR, Dreef EJ, van Kamp H, Fibbe WE, Wessels JW, Beverstock GC, Haak HL, Kluin PM. Detection of monosomy 7 and trisomy 8 in myeloid leukemia : a comparison of banding and fluorescence in situ hybridization. Blood 1993 ; 82 : 904-13.
4. Flactif M, Loi JL, Preudhomme C, Fenaux P. Fluorescence in situ hybridization improves the detection of monosomy 7 in myelodysplastic syndromes. Leukemia 1994 ; 8 : 1012-8.
5. Nylund SJ, Ruutu T, Soarinen U, Larramendy ML, Knuutila S. Detection of minimal residual disease using fluorescence DNA in situ hybridization : a follow-up study in leukemia and lymphoma patients. Leukemia 1994 ; 8, 4 : 587-94.
6. Jenkins RB, Lebeau MM, Kroker WJ, Borell TJ, Stalboerger PG, Davis EM, Penland L, Fernald A, Espinosa R, Schaid DJ, Noel P, Dewald GW. Fluorescence in situ hybridization : a sensitive method for trisomy 8 detection in bone marrow Blood 1992 ; 79 : 3307-15.
7. Heereman NA, Argyropoulos G, Weetman R, Tricot G, Secker-Walter LM. Interphase in situ hybridization reveals minimal residual disease in early remission and return of the diagnostic clone in karyotypically normal relapse of acute lymphoblastic leukemia. Leukemia 1993 ; 4 : 537-43
8. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia : methodologic advances and clinical significance. Blood 1995 ; 85 : 1416-34.
9. Amiel A, Yarkoni S, Slavin S, Or R, Loberboum-Galski H, Fejgin M, Nagler A. Detection of minimal residual disease state in chronic myelogenous leukemia patients using fluorescence in situ hybridization. Cancer Genet Cytogenet 1994 ; 76 : 59-64.
10. Arnoldus EPJ, Wiegant J, Noordermeer IA, Wessels JW, Beverstock GC, Grosveld GC, Van der Ploeg M, Raap AK. Detection of the Philadelphia chromosome in interphase nuclei. Cytogenet Cell Genet 1990 ; 54 : 108-11.
11. Zhao L, Chang KS, Estey EH, Hayes K, Deisseroth AB, Liang JC. Detection of residual leukemic cells in patients with acute promyelocytic leukemia by the fluorescence in situ hybridization method : potential for predicting relapse. Blood 1995 ; 85 ; 495-9.
12. Campana D, Thompson JS, Amlot P, Brown S, Janossy G. The cytoplasmic expression of CD3 antigens in normal and malignant cells of the lymphoide lineage. J Immunol 1987 ; 138 : 648-52.
13. Adriaansen HJA, Jacobs BC, Kappers-Klunne MC, Hahlen K, Hooijkaas H, Van Dongen JJM. Detection of residual disease in AML patients by use of double immunologícal marker analysis for terminal deoxynucleotidyl transferase and myeloid markers. Leukemia 1993 ; 7 : 472-81.
14. + malignant myeloblats has implications for minimal residual disease detection in acute myeloid leukemia. Leukemia 1993 ; 7 : 853-8.
15. Macedo A, Orfao A, Gonzalez M, Vidrioles MB, Lopez-Berges MC, Martinez A, San Miguel JF. Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis : implications for minimal residual disease studies. Leukemia 1995 ; 9 : 993-8.
16. Reading CL, Estey EH, Huh YO, Claxton DF, Sanchez G, Terstappen LWMM, O'Brien MC, Baron S, Deisseroth AB. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood 1993; 81: 3083-90.
17. Drach J, Drach D, Glassl H, Gattringer C, Huber H. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease. Cytometry 1992 ; 13 : 893-901.
18. Fey MF, Kulozik AE, Hansen HT, Tabler A. The polymerase chain reaction : a new tool for the detection fo minimal residual disease in haematological malignancies. Eur J Cancer 1991 ; 27 : 89-94.
19. Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994 ; 372 : 143-9.
20. Sigaux F. Physiologie et pathologie de b recombinaison V (D) J. médecine/sciences 1994 ; 10 : 995-1005.
21. Miller WH, Levine K, Deblasio A, SR F, Dmitrovsky E, Warrell RP. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for PML-RARα fusion mRNA. Blood 1993 ; 82 : 1689-94.
22. Gabert J, Thuret I, Lafage M, Carcassonne Y, Maraninchi D, Mannoni P. Detection of residual bcr/abl translocation by polymerase chain reaction in chronic myeloid leukaemia patients after bone marrow transplantation. Lancet 1989 ; 2 : 1125-8.
23. Bartram CR. Molecular genetic techniques for detection of minimal residual disease in acute lymphoblastic leukemia : possibilities and limitations. Recent Results Cancer Res 1993 ; 131 : 149-55.
24. Aubin J, Davi F, Nguyen-Solomon F, Lebœuf D, Debert C, Taher M, Valensi F, Canioni D, Brousse N, Varef B, Flandrin G, Macintyre E. Description of a novel FR1 IgH strategy and its comparison with three other strategies for the detection of clonality in B-cell malignancies. Leukemia 1995 ; 9 : 471-9.
25. Bockstahler E. Overview of international PCR standardization efforts. PCR Method Applic 1994 ; 3 : 263-7.
26. Sigaux F. Une carte d'identité moléculaire des tumeurs pour une meilleure prise en charge des malades atteints de cancer. Hématologie 1995 ; 1 : 377-8.
27. Sigaux F. Pour une fédération des travaux de recherche sur les hémopathies malignes. Hématologie 1996 ; 2 : 5.
28. Baruchel A, Cayuela JM, Macintyre E, Berger R, Sigaux F. Assessment of clonal evolution at Ig/TCR loci in acute lymphoblastic leukemia by single-strand conformation polymorphism studies and higly resolutive PCR derived method . implication for a general stragegy of minimal residual disease detection. Br J Haematol 1995 ; 90 . 85-93.
29. Thomson JD, Brodsky I, Ynuis JJ. Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation. Blood 1992 ; 79 : 1629-35.
30. Cavé H, Bakkus M, Suciu S, Guidai C, Fournier M, Robert A, Boutard P, Pechinaud F, Plouvier E, Ferster A, Nelken B, Otten J, Thielemans K, Grandchamp B, Vilmer E, Garbarz M. Significance of the quantitation of minimal residual disease by PCR amplification of IGH and TCR gene rearrangements in childhood ALL : a EORTC prospective multicenter study. Blood 1995 ; 86 (suppl. 1) : 178a.
31. Sykkes PJ. Snell LE, Brisco MJ, Neoh SH, Hughes E, Dolman G, Peng LM, Toogood I, Morley AA. Rapid detection of residual disease in a proportion of childhood acute lymphoblastic leukemia patients at the end of induction therapy using polymerase chain reaction. Blood 1995 ; 86 (suppl 1) : 178a.
32. Owen R, Goulden N, Langlands K, Shiach C, Garland R, Knechtli C, Hancock J, Steward C, Potter M, Morgan G, Oakhill, Goldman JM. Comparison of fluorescent consensus IhH PCR and allele specific oligoprobing in the detection of minimal residual disease (MRD) in childhood ALL Blood 1995 ; 86 (suppl. 1) : 738a.
33. Cavé H, Guidal C, Rohdich P, Delfau MH, Broyart A, Lescœur B, Rahimy C, Fenneteau O, Monplaisir N, D'Auriol L, Elion J, Vilmer E, Grandchamp B. Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of δ and γ T-cell receptor genes. Blood 1994 ; 83 : 1892.
34. D'Auriol L, Macintyre E, Galibert F, Sigaux F. In vitro amplification of T-cell gamma gene rearrangements : a new tool for the assessment of minimal residual disease in acute lymphoblastic leukemias. Leukemia 1989 ; 3 : 155.
35. Hansen-Hagge TE, Yokota S, Bartram CR. Dectection of minimal residual disease in acute lymphoblastic leukemia by in vitro amplification of rearranged T-cell receptor delta chain sequences. Blood 1989 ; 74 : 1762.
36. Beishuizen A, Verhoeven MAJ, Van Wering ER, Hohlen K, Hooijkaas H, Van Dongen JJM. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnostic and subsequent relapse : implications for the detection of minimal residual disease by polymerase chain reaction analysis. Blood 1994 ; 83 : 2238-47.
37. Cao J, Vescio R, Hong C, Kim A, Lichtenstein A, Berenson J. Identification of malignant cells in multiple myeloma bone marrow with immunoglobulin VH gene probes by fluorescent in situ hybridization and flow cytometry. J Clin Invest 1995 ; 95 : 904-72.
38. Billadeau D, Quam L, Thomas W, Kay N, Greipp P, Kyle R, Oken MM, Van Ness B. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 1992 ; 80 : 1818-24.
39. Bird JM, Bloxham D, Samson D, Marcus R, Russell N, Kelsey S, Newland A, Apperley J. Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients. Br J Haematol 1994 ; 88 : 110-6.
40. Dreyfus F, Melle J, Quarre MC, Pillier C. Contamination of peripheral blood by monoclonal B cells following treatment of multiple myeloma by high-dose chemotherapy. Br J Haematol 1993 ; 85 : 411-2.
41. Vescio R, Hong C, Cao J, Kim A, Schiller G, Lichtenstein A, Berenson R, Berenson J. The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma. Blood 1994 ; 84 : 3283-90.
42. + stem cells do not contain clonal myeloma cells. Blood 1995 ; 80 : 381-9.
43. + RNA as well as DNA hyperdiploidy and N-RAS mutation. Blood 1995; 86: 1089.
44. Lin F, Goldman JM, Cross NCP. A comparison of the sensibility of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukemia. Br J Haematol 1994 ; 86 : 683-5.
45. Gaiger A, Lion T, Kalhs P, Mitterbauer G, Henn T, Hass O, Fodinger M, Kier P, Forstinger C, Quehenberger P, Hinterberger W, jager U, Linkesch W, Mannhalter C, Lechner K. Frequent detection of BCR-ABL specific mRNA in patients with chronic myeloid leukemia (CML) following allogeneic and syngeneic bone marrow transplantation (BMT). Leukemia 1993 ; 7 : 1766-72.
46. Roth MS, Antin JH, Ash R, Terry VH, Gotlieb M, Silver SM, Ginsburg D. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood 1992 ; 79 : 276-82.
47. Preudhomme C, Wattel E, Lai JL, Henic N, Meyer L, Noel MP, Cosson A, Jouet JP, Fenaux P. Good predictive value of combined cytogenetic and molecular follow-up in chronic myelogenous leukemia after non T-Cell depleted allogeneic bone marrow transplantation : a report on 38 consecutive cases. Leuk Lymph 1995 ; 18 : 265-71.
48. Cross NCP, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993 ; 82 : 1929-36.
49. Malingue MC, Mahon FX, Delfau MH, Daheron L, Kitzis A, Ghilhot F, Tanzer J, Grandchamp B. Quantitative determination of the hybrid Bcr-Abl RNA in patients with chronic myelogenous leukemia under interferon therapy. Br J Haematol 1992 ; 82 : 701-7.
50. Henic N, Preudhomme C, Noel MP, Lai JL, Wetterwald M, Simon M, Fenaux P. Frequency of molecular elimination of Ph1 clone in chronic myelogenous leukemia (CML) with interferon alpha. Leukemia (sous presse).
51. De Thé H. La leucémie aiguë promyélocytaire: aspects moléculaires. Hématologie 1995 ; 1 : 229-38.
52. Hook AT. Oncogenic role of « master » transcription factors in human leukemias and sarcomas : a development model. Adv Cancer Res 1995 ; 67 : 25-56.
53. Nucifora G, Rowley J. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 1995 ; 86 : 1-14.
54. Liu P, Hajra A, Wijmengo C, Collins F. Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia. Blood 1995 ; 85 : 2289-302.
55. Andrieu V, Radford-Weiss I, Troussard X, Chane C, Valensi F, Guesnu M, Haddad E, Viguier F, Dreyfus F, Varet B, Flandrin G. Molecular detection of t(8;21)/AML1-ETO in AML M1/M2 : correlation with cytogenetics, morphology and immunophenotype. Br J Haematol 1995 (sous presse).
56. Poirel H, Radford-Weiss I, Rack K, Troussard X, Veil A, Valensi F, Picard F, Guesnu M, Lebœuf D, Melle J, Dreyfus F, Flandrin G, Macintyre E. Detection or the chromosome 16 CBFb-MYH11 fusion transcript in myelomonocytic leukemias. Blood 1995 ; 85 : 1313-22.
57. Hebert J, Cayuela JM, Daniel MT, Berger R, Sigaux F. Detection of minimal residual disease in acute myelomonocytic leukemia with abnormal marrow oesinophils by nested poly merase chain reaction with allele specific amplification. Blood 1994 ; 84 : 2291-6.
58. Poirel H, Rack K, Delabesse E, I R-W, Troussard X, Debert C, Lebœuf C, Bastard C, Picard F, Veil-Buzyn A, Flandrin G, Bernard O, Macintyre E. Incidence and characterization of MLL gene (11q23) rearrangements in AML M1 and M5. Blood 1995 (sous presse).
59. Nucifora G, Larson RA, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long term remission. Blood 1993 ; 82 : 712-5.
60. Maruyama F, Stass SA, Estey EH, Cork A, Hirano M, Ino T, Freireich E, Yang P, Chang KS. Detection of AML1/ETO fusion transcript as a tool for diagnosing t(8;21) positive acute myelogenous leukemia. Leukemia 1994 ; 8 : 40-5.
61. Kusec R, Laczika K, Knobl P, Friedl J, Greinix H, Kohls P, Linkesch W, Scharzinger I, Mitterbauer G, Purtscher B, Haas OA, Lechner K, Jaeger U. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 1994 ; 8 : 735-9.
62. Preudhomme C, Philippe N, Macintyre E, Lai JL, Jouet JP, Cosson A, Fenaux P. Persistance of AML1/ETO fusion mRNA in t(8;21) acute myeloid leukemia (AML) in prolonged remission : is there a consensus ? Leukemia (sous presse).
63. Satake N, Maseki N, Kozu T, Sakashita A, Kobayashi H, Sakurai M, Ohki M, Kaneko Y. Disappearance of AML1-MTG8 (ETO) fusion transcript in acute myeloid leukaemia patients with t(8;21) in long term remission. Br J Haematol 1995 ; 91 : 892-8.
64. Muto A, Mori S, Matsushita H, Ueno H, Takayama N, Kizaki M, Ikeda Y. Development and clinical evaluation of quantification of the minimal residual disease in t(8;21) leukemia with novel RT-competitive PCR assay. Blood 1995 ; 86 (suppl. 1) : 331a.
65. Castaigne S, Balitrand N, De Thé H. Dejean A, Degos L, Chomienne C. A PML-RARα fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia. Blood 1992 ; 79 : 3110-5.
66. Chomienne C. RT-PCR in acute promyelotic leukemia. Second workshop of the European retinoic group. Paris, France, december 17-18, 1994. Leukemia (sous presse).
67. Fenaux P, Chastang C, Chomienne C, Degos L. Tretinoin with chemotherapy in newly diagnosed acute promyelocytic leukeamia. Lancet 1994 ; 343 : 1033.
68. Gabert J, Macintyre E, Raynaud S, Cayuela JM, Bilhou-Nabera C; Debuire B, Deschaseaux M, Bories D, Bastard C, Davi F, Martiat P, Durieux E, Fière D. Analyse moléculaire des t(9,22), t(4;11), t(1;19) et t(12;21) au diagnostic des LAL de l'adulte : l'expérience du groupe de biologie moléculaire du LALA94. Nouv Rev Fr Hématol 1996 (sous presse).
69. Maurer J, Janssen JW, Thiel E, Van DJ, Ludwig WD, Aydemir U, Heinze B, Fonatsch C, Harbott J, Reiter A, Riehm H, Hoelzer D, Bartram CR. Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet 1991 ; 337 : 1055-8.
70. Kawasaki ES, Clark SS, Coyne MY, Smith SD, Champlin R, Witte ON, McCormick FP. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci USA 1988 ; 85 : 5698-702.
71. Izraeli S, Janssen JW, Haas OA, Harbott J, Brok SF, Walther JU, Kovar H, Henn T, Ludwig WD, Reiter A, Rechavi G, Bartram CR, Gadner H, Lion T. Detection and clinical relevance of genetic abnormalities in pediatric acute lymphoblastic leukemia : a comparison between cytogenetic and polymerase chain reaction analyses. Leukemia 1993 ; 7 ; 671-8.
72. Tigaud I, Tigaud JD, Rouault JP, Rimokh R, Samarut C, Magaud JP. Remaniements de la bande chromosomique 11q23 dans les hémopathies malignes. Hématologie 1995 ; 1 : 319-24.
73. Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC, Bray-Ward P, Morgan E, Raimondi SC, Rowley JD, Gilliland DG. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA 1995; 92 : 4917-21.
74. Romana SP, Mauchauffé M, Le Coniat M, Chumakov I, Le Paslier D, Berger R, Bernard O. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood 1995; 85: 3662-8.
75. Romana SP, Poirel H, Le Coniat M, Flexor MA, Mauchauffé M, Jouveaux P, Macintyre E, Berger R, Bernard O. High frequency of t(12;21) in childhood B lineage acute lymphoblastic leukemia Blood 1995; 80: 4263-7.
76. Raynaud S, Cavé H, Baens M, Bastard C, Cacheux V, Grosgeorge J, Guidal-Giroud C, Guo C, Vilmer E, Marynen P, Grandchamp B. The (12;21) translocation involving TEL and deletion of the other TEL allele : two frequently associated alterations in childhood acute lymphoblastic leukemia. Blood (sous presse).
77. Cayuela JM, Baruchel A, Orange C, Madani A, Auclerc MF, Daniel MT, Schaison G, Sigaux F. TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia. Blood (sous presse).
78. Shurtleef SA, Buijs A, Behm FG, Rubnitz JE, Raimondi SC, Hancock ML, Head DR, Pui CH, Grosveld G, Downing JR. TEL/AML1 fusion occurs in 28 % of pediatric progenitor cell accute lymphoblastic leukemia (ALL) and defines a subgroup of patients with a favorable prognosis. Blood 1995 ; 80 (suppl. 1) : 598a.
79. Liu Y, Hernandez A, Shibata D, Cortopassi GA. Bcl2 translocation frequency rises with age in humans. Proc Natl Acad Sci USA 1994 ; 91 : 8910-4.
80. Limpens J, Stad R, Vos C, De Vlaam C, Van Ommen G, Schuuring E, Kluin PM. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood 1995 ; 85 : 2528-36.
81. Limpens J, De Jong D, Van Krieken J, Price C, Young S, Van Ommen G, Kluin PM. Bcl-2/JH rearrangements in benign lymphoid tissues with follicular hyperplasie. Oncogene 1991 ; 6 : 2271-6.
82. Delage B, Roy J, Bemier V, Delage JM, Darveau A. Multiple Bcl 2-JH gene rearrangements in patients with chronic polyclonal B-cell lumphocytosis: Blood 1995; 86 (suppl. 1) : 727a.
83. Dölken G, Illerhaus G, Hirt C. Long-lived t(14;18) positive B cells are circulating in the peripheral blood of healthy donors. Blood 1995 ; 86 (suppl. 1) : 605a.
84. O'Reilly J, Meyer B, Baker D, Herrmann R, Cannell P, Davles T. Correlation of bone marrow minimal residual disease and apparent isolated extra-medullary relapse in childhood acute lymphoblastic leukaemia. Leukemia 1995 ; 9 : 624-7.
85. Brisco MJ, Condon J, Hughes E, Negh SH, Sykes PJ, Seshadri R, Toogood I, Waters K, Tauro G, Ekert H. Outcome prediction in childhood acute lymphoblastic leukemia by molecular quantification of residual disease at the end of induction. Lancet 1994 ; 343 : 196-9.
86. Wasserman R, Galili N, Iio Y, Silber JH, Reichard BA, Shane S, Womer RB, Lange B, Rovera G. Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lincage acute lymphoblastic leukemia. J Clin Oncol 1992 ; 10 : 1879-88.
87. Mahon FX, Daheron L, Malinge MC, Ahmad M, Delfau MH, Grandchamp B, Kitzis A, Tanzer J, Guilhot F. Polymerase chain reaction detection of residual disease in chronic myelocytic leukemia in complete cytogenetic remission under interferon with or without chemotherapy. Leukemia 1992 ; 6 : 1232-4.
88. Seong DC, Kantarjian HM, Ro JY, Talpaz M, Xy J, Robinson JR, Deisseroth AB, Champlin RE, Siciliano MJ. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood 1995 ; 86 : 2343-9.